RGNT Regentis Biomaterials Ltd.
Financings ·
Regentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026.
Regentis Biomaterials Ltd. filed a Form F-1 on May 1, 2026 for a firm commitment offering through ThinkEquity. The $3.00 price is the April 28, 2026 NYSE American close.
Regentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. The company reported $7.4 million in cash at December 31, 2025, and its pivotal knee cartilage trial is still enrolling.
| Line | FY2025 | FY2024 |
|---|---|---|
| Net income (loss) | -$13.6 million | $4.8 million |
| Cash from operations | -$1.4 million | -$641,000 |
| Cash and equivalents | $7.4 million |
Our latest story on this, dated Feb 24, 2026: "Regentis Biomaterials discloses going concern qualification in 2025 audit opinion". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 11, 2026: "Regentis reports $9.0 million cash after $6.5 million June private placement". The story links the filing or release it is based on. Read the story.
Regentis Biomaterials Ltd. trades under the ticker RGNT on AMEX.
Regentis Biomaterials Ltd. is listed on AMEX.
The SEC Central Index Key (CIK) for Regentis Biomaterials Ltd. is 1912966. Its filings are on SEC EDGAR.
5,179,378 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-02-24.
Our directory records Regentis Biomaterials Ltd. under Israel.
Our directory classifies Regentis Biomaterials Ltd. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Regentis Biomaterials Ltd. is IL0012190968.
aibio.space lists Regentis Biomaterials Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
Regentis Biomaterials Ltd. reported a net loss of $13.6 million for the fiscal year ended Dec 31, 2025, and used $1.4 million of cash in operations, per its annual report to the SEC.
$7.4 million in cash at Dec 31, 2025, per its 20-F/A.
Our latest story on Regentis Biomaterials, dated Sep 11, 2026: "Regentis reports $9.0 million cash after $6.5 million June private placement". Regentis Biomaterials reported on September 11, 2026 that it had about $9.0 million in cash at June 30, 2026, after a $6.5 million private placement in June. It says it has repaid its debt entirely, and it now expects the U.S. pivotal trial of GelrinC to finish enrolling at about year end 2026. Source.
From our story of Feb 24, 2026: Regentis Biomaterials said on February 24, 2026 that its auditor's opinion on the 2025 financial statements carries a going concern qualification. Source.
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Reported a financing. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio